Martine Rothblatt sold 2,628 shares of United Therapeutics Corp ($UTHR) on October 12, 2026. The open-market transaction carried a price of $551.1025 per share, for a total value of $1,448,297.37. A Form 4 reached the SEC on October 13, 2026, one day after the trade date. Rothblatt held 326,993 $UTHR shares after the transaction.
Rothblatt's October 12 activity included more than that single sale. The database recorded seven open-market $UTHR sales dated October 12 under Rothblatt, representing 9,500 shares and a combined disclosed value of roughly $5.23 million. Individual sale values ranged from $74,851.67 to $1,448,297.37. Per-share prices fell between $548.1287 and $554.4568. Each transaction in the group was an open-market sale. The largest of the seven was the 2,628-share block at $551.1025 per share.
The recent $UTHR insider transaction record contained only sales. The 40 most recent $UTHR insider trades returned by the database were all open-market sales attributed to Rothblatt, with a combined disclosed value of about $18.65 million. No other $UTHR insider appeared in that set. The group included 12 sales dated October 9 with a combined disclosed value of about $4.22 million, 11 sales dated September 24 with a combined disclosed value of about $4.50 million, and 10 sales dated September 22 with a combined disclosed value of about $4.70 million. Across the October 12 and October 9 sales alone, the combined disclosed value was about $9.45 million. None of the 40 transactions was a purchase. The October 9 sales carried an October 13 filing date, four days after the trade date. The September 22 sales carried a September 23 filing date, and the September 24 sales carried a September 25 filing date.
No $UTHR STOCK Act disclosures dated in 2026 appeared in the congressional database. The most recent entries were from late October 2025. Representative Lisa Mcclain disclosed a purchase on October 30, 2025 and a sale the same day, plus a sale on October 31, 2025. Each of Mcclain's three entries carried a midpoint value of $1,001. Representative Michael T. McCaul disclosed a sale on October 27, 2025, with a midpoint value of $15,001. Congressional dollar amounts are midpoint estimates of the disclosed bracketed ranges.
United Therapeutics is a biotechnology company with a market capitalization of about $23.38 billion as of the database record. The October 12 per-share price of $551.10 was above the range recorded in Rothblatt's September 22 sales, which ran from $489.61 to $499.07. It was also above the September 24 range of $469.74 to $480.33. The October 13 filing followed the October 12 trade date by one day.